342.a An emerging issue: Carbapenem resistant enterobacteriaceae in solid-organ tx
Hande Arslan, Turkey
342.b Beneficial impact of immunosuppressive and anti-retroviral regimens on outcomes following kidney transplantation in people living with HIV
Peter G. Stock, United States
342.1 Risk factors for vancomycin resistant enterococci (VRE) colonization in liver transplantation: A retrospective cohort study
Miss Nathalia Neves Nunes, Brazil
342.2 ATG dose is associated with CMV viremia but not BK viremia in living donor kidney transplants
Dr. Isik H Ozgu, Turkey
342.3 Comparison of risk factors and outcome between high and low Cytomegalovirus viremia in living donor R+D+ renal transplant recipients from Pakistan
Prof. Ejaz Ahmed, Pakistan
342.4 Unmasking the danger: Investigating factors predisposing liver transplant recipients to invasive fungal infections
Dr. Katheresan V, India
342.5 Clinical course, management and outcomes of COVID-19 in HIV-infected renal transplant recipients: A case series
Dr. Laurie L Bertels, South Africa
342.6 Kidney transplantation in the biggest Croatian abdominal organs transplantation center during COVID-19 pandemics (11 March 2020 – 11 May 2023)
Dr. Ksenija Vučur Šimić, Croatia
342.7 BKV nephropathy in kidney transplant recipients: Management and outcome
Mrs. Theodora Penna, Greece
342.8 Retrospective review of ART regimens in HIV-positive to HIV-positive kidney transplant recipients
Kathryn Manning, South Africa
342.9 Etiology of Diarrhea in Renal Allograft Recipients using FilmArray GI panel test and Graft Outcome at a tertiary care centre from India.
Presenter will be Dr Yogita sharma
Dr. Yogita Sharma, India
342.10 Evaluation of CMV Hyperimmunoglobulin Use in a large European non-interventional, multicenter study after heart and lung transplantation
Markus J. Barten, Germany
342.11 Chagas transmission in kidney transplants: Impact of post-transplant benzonidazole prophylaxis